LOS GATOS, CA / ACCESSWIRE / January 9, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced that Chief Financial Officer Kevin Williamson will host one-on-one investor meetings in San Francisco, CA during the week of January 13th in accordance with the 43rd Annual J.P. Morgan Healthcare Conference.The J.P. Morgan Healthcare Conference is the industry's leading global investment forum, bringing together top executives, investors, and innovators across the healthcare ecosystem. With over 500 healthcare companies presenting, the event showcases groundbreaking advanc

~ 3Q Revenue of $0.9 Million, Consistent with Prior Quarter; Year to Date Revenue of $2.5 Million, Growth of 18.3% Compared to Prior Year ~~ Published Interim Analysis from MAINSAIL™ Study; Post-Market Study Supports the Safety and Efficacy of the Catamaran SI Joint Fusion System® Including Radiographic Proof of Fusion ~~ Initial Clinical Procedures Completed with New Catamaran SE Platform ~~ Granted Issuance of Three U.S. Patents ~~ Received Net Proceeds of ~$9.6 Million from Equity Financing Transactions ~ LOS GATOS, CA / ACCESSWIRE / November 13, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering from certain Sac

~ Procedures Completed in Various Spine & Pain Centers of Excellence Throughout the Country Including in Idaho, Pennsylvania, Minnesota, Arizona and Utah ~~Feedback From Initial Physician Users to Support Broader Market Introduction~ LOS GATOS, CA / ACCESSWIRE / October 30, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced completion of the initial clinical cases utilizing the Company's new Catamaran SE SI Joint Fixation Device. The new implant offers a 30% reduction in implant width as compared to the original Catamaran Fixation Device, providing physicians wi

LOS GATOS, CA / ACCESSWIRE / October 30, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced plans to release financial results for the third quarter 2024 ended September 30, 2024 after market close on Wednesday, November 13, 2024. The Company will also hold a conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.Date:Wednesday, November 13, 2024Time:4:30 p.m. Eastern timeDial-in:1-800-717-1738International Dial-in:1-646-307-1865Webcast:TNON C

LOS GATOS, CA / ACCESSWIRE / October 28, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced that it is in compliance with all relevant Nasdaq continued listing Rules. The Company had previously reported non compliance with Nasdaq Rules 5605(b)(1), 5605(c)(2) and 5605(d)(2), with respect to the number of independent directors on its board of directors and certain board committees; Nasdaq Rule 5550(a)(2), with respect to its minimum bid price; Nasdaq Rule 5550(a)(4), with respect to number of shares in its public float; and Nasdaq Rule 5550(b), with respect to its

Further Solidifies International Patent Portfolio and Underscores the Company's Commitment to Innovation of SI Joint Stabilization Systems and Methods LOS GATOS, CA / ACCESSWIRE / October 17, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the issuance of U.S. Patent Nos. 12,115,075, 12,115,076 and 12,115,077.U.S. Patent Nos. 12,115,075 and 12,115,076, both entitled "Sacroiliac Joint Stabilization Prostheses", are directed to Tenon's enhanced Catamaran® prostheses that include unique drug delivery compositions, which enhance sealing of the prostheses in SI jo

Tenon Now Holds 9 Granted Patents and 26 Pending Applications for the Catamaran® SI Joint Fusion System Worldwide LOS GATOS, CA / ACCESSWIRE / September 19, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the United States Patent and Trademark Office ("USPTO") issued three (3) Notices of Allowance for U.S. Patent Application Numbers 17,469,132 and 17/468,811, both entitled "Sacroiliac Joint Stabilization Prostheses", and 18/612,032, entitled "Systems, Apparatus and Methods for Stabilizing Sacroiliac Joints". The U.S. patents based on the applications should t

LOS GATOS, CA / ACCESSWIRE / September 17, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced the closing of its previously announced "reasonable best efforts" public offering with a single health-care focused institutional investor for the purchase and sale of 1,222,850 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,222,850 shares of common stock at a combined offering price of $3.68 per share and accompanying warrant, priced at-the-market under Nasdaq rules (the "Offering"). The Company received aggregate

LOS GATOS, CA / ACCESSWIRE / September 12, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced the pricing of its "reasonable best efforts" public offering with a single health-care focused institutional investor for the purchase and sale of up to 1,222,850 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,222,850 shares of common stock at a combined offering price of $3.68 per share and accompanying warrant, priced at-the-market under Nasdaq rules (the "Offering"). The Company expects to receive aggregate gross

~ New SI Joint Fixation Device Offers a 30% Reduction in Implant Size Providing Physicians Choices for Varying Anatomy and Treatment Strategies with the Catamaran Technology ~~The SE System Can Also Be Utilized with a Manual Drilling Option During Implant Preparation~ LOS GATOS, CA / ACCESSWIRE / September 12, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced preparation for the initial alpha launch of the Company's new Catamaran SE SI Joint Fusion System targeted for the beginning of Q4. The Catamaran SE Fixation Device extends the line of implant offerings fo

LOS GATOS, CA / ACCESSWIRE / August 27, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has appointed Kevin Williamson as Chief Financial Officer. Mr. Williamson's appointment succeeds the previously disclosed retirement of Steve Van Dick from the role of Chief Financial Officer.Mr. Williamson most recently served as the Chief Financial Officer at Accelus Inc., a medical device company focused on expandable spinal implant technology. In this role, Mr. Williamson was responsible for the finance organization, in addition to the investor relation

Experienced Medical Devices Industry Executive Joins Tenon's Board of DirectorsLOS GATOS, CA / ACCESSWIRE / March 28, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced that Kristine Jacques has been appointed as an independent member of the Company's Board of Directors on March 25, 2024, effective immediately. Following this appointment, Tenon Medical's Board of Directors consists of seven members, including four independent directors.During her impressive career spanning over 35 years, Ms. Jacques brings extensive experience in various executive leadership roles in

10-Q - Tenon Medical, Inc. (0001560293) (Filer)

424B3 - Tenon Medical, Inc. (0001560293) (Filer)

EFFECT - Tenon Medical, Inc. (0001560293) (Filer)

D - Tenon Medical, Inc. (0001560293) (Filer)

D - Tenon Medical, Inc. (0001560293) (Filer)

D - Tenon Medical, Inc. (0001560293) (Filer)

S-1 - Tenon Medical, Inc. (0001560293) (Filer)

8-K - Tenon Medical, Inc. (0001560293) (Filer)

8-K - Tenon Medical, Inc. (0001560293) (Filer)

424B5 - Tenon Medical, Inc. (0001560293) (Filer)

3 - Tenon Medical, Inc. (0001560293) (Issuer)

3 - Tenon Medical, Inc. (0001560293) (Issuer)

5 - Tenon Medical, Inc. (0001560293) (Issuer)

5 - Tenon Medical, Inc. (0001560293) (Issuer)

5 - Tenon Medical, Inc. (0001560293) (Issuer)

4 - Tenon Medical, Inc. (0001560293) (Issuer)

4 - Tenon Medical, Inc. (0001560293) (Issuer)

4 - Tenon Medical, Inc. (0001560293) (Issuer)

4 - Tenon Medical, Inc. (0001560293) (Issuer)

4 - Tenon Medical, Inc. (0001560293) (Issuer)

LOS GATOS, CA / ACCESSWIRE / October 30, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced plans to release financial results for the third quarter 2024 ended September 30, 2024 after market close on Wednesday, November 13, 2024. The Company will also hold a conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.Date:Wednesday, November 13, 2024Time:4:30 p.m. Eastern timeDial-in:1-800-717-1738International Dial-in:1-646-307-1865Webcast:TNON C

~ Second Quarter 2024 Revenue Increased 21% Year-Over-Year ~~ Surgical Procedures Increased 7% Year-Over-Year in the Second Quarter 2024 ~~ Gross Profit Margin of 52% Marks One Year of Generating Positive Gross Profit ~~ Publication of Post-Market Study Interim Analysis Now Imminent ~ LOS GATOS, CA / ACCESSWIRE / August 13, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today reported financial results for the second quarter ended June 30, 2024.Second Quarter 2024 and Subsequent HighlightsRevenue of $901,000 in the second quarter of 2024, a 21% increase over th

LOS GATOS, CA / ACCESSWIRE / July 30, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced plans to release financial results for the second quarter 2024 ended June 30, 2024 after market close on Tuesday, August 13, 2024. The Company will also hold a conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.Date:Tuesday, August 13, 2024Time:4:30 p.m. Eastern timeDial-in:1-877-407-0792International Dial-in:1-201-689-8263Webcast:TNON Conference

~ Revenue Increased 66% Year-Over-Year ~~ Surgical Procedures Increased 42% Year-Over-Year ~~ Gross Margin Stabilized at 65% Sequentially ~~ Catamaran® SI Joint Fusion System Received Positive Fusion Results from Post-Market Study ~ LOS GATOS, CA / ACCESSWIRE / May 14, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today reported financial results for the first quarter ended March 31, 2024.First Quarter 2024 HighlightsRevenue of $719,000 in the first quarter of 2024, a 66% increase over the prior year quarter.Gross profit of $470,000 as compared to a gross loss

LOS GATOS, CA / ACCESSWIRE / April 30, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced plans to release financial results for the first quarter 2024 ended March 31, 2024 after market close on Tuesday, May 14, 2024. The Company will also hold a conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.Date:Tuesday, May 14, 2024Time:4:30 p.m. Eastern timeDial-in:1-877-407-0792International Dial-in:1-201-689-8263Webcast:TNON Conference CallP

Fourth Quarter 2023 Revenue Increased 192% Year-Over-YearFull Year 2023 Revenue Increased 324% Year-Over-YearSurgical Procedures Increased 179% Year-Over-Year in the Fourth Quarter and 312% for the Full Year 2023Achieved Three Consecutive Quarters of Positive Gross Profit Margin in 2023Catamaran® SI Joint Fusion System Included in a Series of Immersive Physician Webinar Training Programs Attended by Sixty Healthcare Providers in Q4LOS GATOS, CA / ACCESSWIRE / March 12, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today reported financial results for the fourt

LOS GATOS, CA / ACCESSWIRE / February 27, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced plans to release financial results for the fourth quarter and full year 2023 ended December 31, 2023 after market close on Tuesday, March 12, 2024. The Company will also hold a conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.Date:Tuesday, March 12, 2024Time:4:30 p.m. Eastern timeDial-in:1-877-407-0792International Dial-in:1-201-689-8263Webc

~ Revenue Increased 354% Year-Over-Year to $944,000 ~~ Gross Profit Margin of 57% an Increase of 31 Basis Points Sequentially ~~ Surgical Procedures Increased 329% in the Third Quarter ~~ Concluded the Quarter with the Surgical Launch of the JIB Instrument Kit for the Catamaran® SI Joint Fusion System ~LOS GATOS, CA / ACCESSWIRE / November 14, 2023 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacroiliac disorders, today reported financial results for the third quarter ended September 30, 2023.Third Quarter 2023 and Subsequent HighlightsRevenue of $944,000, a 354% increase over the prior year quarter, a

LOS GATOS, CA / ACCESSWIRE / November 2, 2023 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced plans to release financial results for the third quarter 2023 ended September 30, 2023 after market close on Tuesday, November 14, 2023. The Company will also hold a conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call with conclude with a Q&A session with its covering analysts.Date:Tuesday, November 14, 2023Time:4:30 p.m. Eastern timeDial-in:1-877-407-0792International Dial-in:1-201-689-8263Webcast:TNON

LOS GATOS, CA / ACCESSWIRE / July 25, 2023 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac disorders, today announced plans to release financial results for the second quarter 2023 ended June 30, 2023 after market close on Tuesday, August 8, 2023. The Company will also hold a conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call with conclude with a Q&A session with its covering analysts.Date:Tuesday, August 8, 2023Time:4:30 p.m. Eastern timeDial-in:1-800-830-9649International Dial-in:1-213-992-4624Webcast:TNON Conference CallPlease dial in

SC 13G - Tenon Medical, Inc. (0001560293) (Subject)

SC 13G - Tenon Medical, Inc. (0001560293) (Subject)

SC 13G/A - Tenon Medical, Inc. (0001560293) (Subject)

SC 13G - Tenon Medical, Inc. (0001560293) (Subject)

SC 13G/A - Tenon Medical, Inc. (0001560293) (Subject)

SC 13G/A - Tenon Medical, Inc. (0001560293) (Subject)